Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies to treat autoimmune diseases using its proprietary CARTA platform. The company's lead candidate, rese-cel, is a CD19-targeted CAR T cell therapy designed to deplete disease-causing B cells and reset immune function through a single infusion, with clinical trials underway across multiple autoimmune indications including lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. The company plans to generate revenue from product sales of rese-cel as an autologous cell therapy administered in an outpatient setting, targeting the U.S. market initially with expansion to international markets.